Psilocin, the active metabolite of psilocybin, is a psychedelic and agonist at the serotonin 2A receptor (5-HT2AR) that has shown positive therapeutic effects for brain disorders such as depression. To elucidate the brain effects of psilocybin, we directly compared the acute effects of 5-HT2AR agonist (psilocybin) and antagonist (ketanserin) on cerebral blood flow (CBF) using pseudo-continuous arterial spin labeling magnetic resonance imaging (MRI) in a single-blind, cross-over study in 28 healthy participants. We evaluated associations between plasma psilocin level (PPL) or subjective drug intensity (SDI) and CBF. We also evaluated drug effects on internal carotid artery (ICA) diameter using time-of-flight MRI angiography. PPL and SDI were significantly negatively associated with regional and global CBF (∼11.6% at peak drug effect, p < 0.0001). CBF did not significantly change following ketanserin (2.3%, p = 0.35). Psilocybin induced a significantly greater decrease in CBF compared to ketanserin in the parietal cortex (pFWER < 0.0001). ICA diameter was significantly decreased following psilocybin (10.5%, p < 0.0001) but not ketanserin (−0.02%, p = 0.99). Our data support an asymmetric 5-HT2AR modulatory effect on CBF and provide the first in vivo human evidence that psilocybin constricts the ICA, which has important implications for understanding the neurophysiological mechanisms underlying its acute effects.
Carhart-HarrisRLBolstridgeMRuckerJ, et al.
Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry2016;
3: 619–627.
2.
DavisAKBarrettFSMayDG, et al.
Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial. JAMA Psychiatry2021;
78: 481–489.
3.
GoodwinGMAaronsonSTAlvarezO, et al.
Single-dose psilocybin for a treatment-resistant episode of major depression. N Engl J Med2022;
387: 1637–1648.
4.
GriffithsRRJohnsonMWCarducciMA, et al.
Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. J Psychopharmacol Oxf Psychopharmacol2016;
30: 1181–1197.
5.
GrobCSDanforthALChopraGS, et al.
Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch Gen Psychiatry2011;
68: 71–78.
6.
BogenschutzMPRossSBhattS, et al.
Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: a randomized clinical trial. JAMA Psychiatry2022;
79: 953–962.
7.
JohnsonMWGarcia-RomeuACosimanoMP, et al.
Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. J Psychopharmacol Oxf Psychopharmacol2014;
28: 983–992.
8.
McCulloch DE-W, Grzywacz MZ, Madsen MK, et al. Psilocybin-induced mystical-type experiences are related to persisting positive effects: A quantitative and qualitative report. Front Pharmacol 2022; 13: 841648.
9.
PrellerKHVollenweiderFX.Phenomenology, structure, and dynamic of psychedelic states. Curr Top Behav Neurosci2018;
36: 221–256.
10.
GriffithsRRJohnsonMWRichardsWA, et al.
Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. Psychopharmacology (Berl)2011;
218: 649–665.
11.
GriffithsRRichardsWJohnsonM, et al.
Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. J Psychopharmacol Oxf Psychopharmacol2008;
22: 621–632.
12.
MadsenMKFisherPMStenbækDS, et al.
A single psilocybin dose is associated with long-term increased mindfulness, preceded by a proportional change in neocortical 5-HT2A receptor binding. Eur Neuropsychopharmacol J Eur Opsychopharmacol2020;
33: 71–80.
13.
StenbækDSMadsenMKOzenneB, et al.
Brain serotonin 2A receptor binding predicts subjective temporal and mystical effects of psilocybin in healthy humans. J Psychopharmacol Oxf Psychopharmacol2021;
35: 459–468.
14.
MacLeanKAJohnsonMWGriffithsRR.Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness. J Psychopharmacol Oxf Psychopharmacol2011;
25: 1453–1461.
15.
ErritzoeDRosemanLNourMM, et al.
Effects of psilocybin therapy on personality structure. Acta Psychiatr Scand2018;
138: 368–378.
16.
GriffithsRRRichardsWAMcCannU, et al.
Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology (Berl)2006;
187: 268–283; discussion 284-292.
17.
SøndergaardAMadsenMKOzenneB, et al.
Lasting increases in trait mindfulness after psilocybin correlate positively with the mystical-type experience in healthy individuals. Front Psychol2022;
13: 948729.
18.
HoritaAWeberLJ.Dephosphorylation of psilocybin to psilocin by alkaline phosphatase. Proc Soc Exp Biol Med1961;
106: 32–34.
19.
HalberstadtALGeyerMA.Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens. Neuropharmacology2011;
61: 364–381.
VollenweiderFXVollenweider-ScherpenhuyzenMFIBäblerA, et al.
Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. NeuroReport1998;
9: 3897–3902.
22.
PrellerKHHerdenerMPokornyT, et al.
The fabric of meaning and subjective effects in LSD-induced states depend on serotonin 2A receptor activation. Curr Biol2017;
27: 451–457.
23.
KometerMSchmidtAJänckeL, et al.
Activation of serotonin 2A receptors underlies the psilocybin-induced effects on α oscillations, N170 visual-evoked potentials, and visual hallucinations. J Neurosci Off J Urosci2013;
33: 10544–10551.
24.
HalberstadtALGeyerMA.Characterization of the head-twitch response induced by hallucinogens in mice: detection of the behavior based on the dynamics of head movement. Psychopharmacology (Berl)2013;
227: 727–739.
25.
QuednowBBKometerMGeyerMA, et al.
Psilocybin-induced deficits in automatic and controlled inhibition are attenuated by ketanserin in healthy human volunteers. Neuropsychopharmacology2012;
37: 630–640.
26.
BeckerAMKlaiberAHolzeF, et al.
Ketanserin reverses the acute response to LSD in a randomized, double-blind, placebo-controlled, crossover study in healthy participants. Int J Neuropsychopharmacol2023;
26: 97–106.
27.
VarnäsKHalldinCHallH.Autoradiographic distribution of serotonin transporters and receptor subtypes in human brain. Hum Brain Mapp2004;
22: 246–260.
28.
MinerL. a HBackstromJRSanders-BushE, et al.
Ultrastructural localization of serotonin2A receptors in the middle layers of the rat prelimbic prefrontal cortex. Neuroscience2003;
116: 107–117.
29.
JakabRLGoldman-RakicPS.5-Hydroxytryptamine2A serotonin receptors in the primate cerebral cortex: possible site of action of hallucinogenic and antipsychotic drugs in pyramidal cell apical dendrites. Proc Natl Acad Sci U S A1998;
95: 735–740.
30.
UllmerCSchmuckKKalkmanHO, et al.
Expression of serotonin receptor mRNAs in blood vessels. FEBS Lett1995;
370: 215–221.
31.
NagatomoTRashidMAbul MuntasirH, et al.
Functions of 5-HT2A receptor and its antagonists in the cardiovascular system. Pharmacol Ther2004;
104: 59–81.
32.
WattsSWDavisRP.5-Hydroxtryptamine receptors in systemic hypertension: an arterial focus. Cardiovasc Ther2011;
29: 54–67.
33.
ConnorHEFeniukWHumphreyPP.5-Hydroxytryptamine contracts human coronary arteries predominantly via 5-HT2 receptor activation. Eur J Pharmacol1989;
161: 91–94.
34.
BaxWAVan Heuven-NolsenDBosE, et al.
5-Hydroxytryptamine-induced contractions of the human isolated saphenous vein: involvement of 5-HT2 and 5-HT1D-like receptors, and a comparison with grafted veins. Naunyn Schmiedebergs Arch Pharmacol1992;
345: 500–508.
35.
VerheggenRFreudenthalerSMeyer-DulheuerF, et al.
Participation of 5-HT1-like and 5-HT2A receptors in the contraction of human temporal artery by 5-hydroxytryptamine and related drugs. Br J Pharmacol1996;
117: 283–292.
36.
YakovlevDSSpasovAAMal’tsevDV, et al.
Effect of 5-HT(2A) receptor antagonists on blood flow in the carotid vessels upon elevation of serotonin level. Bull Exp Biol Med2014;
157: 350–352.
37.
Mohammad-ZadehLFMosesLGwaltney-BrantSM.Serotonin: a review. J Vet Pharmacol Ther2008;
31: 187–199.
38.
McCullochDE-WKnudsenGMBarrettFS, et al.
Psychedelic resting-state neuroimaging: a review and perspective on balancing replication and novel analyses. Neurosci Biobehav Rev2022;
138: 104689.
39.
VollenweiderFXPrellerKH.Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders. Nat Rev Neurosci2020;
21: 611–624.
40.
CummingPScheideggerMDornbiererD, et al.
Molecular and functional imaging studies of psychedelic drug action in animals and humans. Mol Basel Switz2021;
26: 2451.
41.
Carhart-HarrisRLErritzoeDWilliamsT, et al.
Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proc Natl Acad Sci U S A2012;
109: 2138–2143.
42.
LewisCRPrellerKHKraehenmannR, et al.
Two dose investigation of the 5-HT-agonist psilocybin on relative and global cerebral blood flow. NeuroImage2017;
159: 70–78.
43.
RieserNMGubserLPMoujaesF, et al.
Psilocybin-induced changes in cerebral blood flow are associated with acute and baseline inter-individual differences. Sci Rep2023;
13: 17475.
44.
HermleLFünfgeldMOepenG, et al.
Mescaline-induced psychopathological, neuropsychological, and neurometabolic effects in normal subjects: experimental psychosis as a tool for psychiatric research. Biol Psychiatry1992;
32: 976–991.
45.
VollenweiderFXLeendersKLScharfetterC, et al.
Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis. Neuropsychopharmacology1997;
16: 357–372.
46.
MadsenMKFisherPMBurmesterD, et al.
Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels. Neuropsychopharmacology2019;
44: 1328–1334.
47.
MadsenMKStenbækDSArvidssonA, et al.
Psilocybin-induced changes in brain network integrity and segregation correlate with plasma psilocin level and psychedelic experience. Eur Neuropsychopharmacol J Eur Opsychopharmacol2021;
50: 121–132.
48.
OlsenASLykkebo-ValløeAOzenneB, et al.
Psilocybin modulation of time-varying functional connectivity is associated with plasma psilocin and subjective effects. NeuroImage2022;
264: 119716.
49.
McCulloch DE-W, Olsen AS, Ozenne B, et al. Navigating the chaos of psychedelic fMRI brain-entropy via multi-metric evaluations of acute psilocybin effects. MedRxiv 2024; 2023.07.03.23292164.
50.
EttrupAda Cunha-BangSMcMahonB, et al.
Serotonin 2A receptor agonist binding in the human brain with [11C]cimbi-36. J Cereb Blood Flow Metab Off J Tab2014;
34: 1188–1196.
51.
HolzeFMadsenMKSvarerC, et al.
Ketanserin exhibits dose- and concentration-proportional serotonin 2A receptor occupancy in healthy individuals: Relevance for psychedelic research. Eur Neuropsychopharmacol J Eur Opsychopharmacol2024;
88: 43–48.
52.
KolaczynskaKELiechtiMEDuthalerU.Development and validation of an LC-MS/MS method for the bioanalysis of psilocybin’s main metabolites, psilocin and 4-hydroxyindole-3-acetic acid, in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci2021;
1164: 122486.
53.
JenkinsonMBeckmannCFBehrensTEJ, et al.
FSL. NeuroImage2012;
62: 782–790.
54.
AnderssonJLRSkareSAshburnerJ.How to correct susceptibility distortions in spin-echo echo-planar images: application to diffusion tensor imaging. NeuroImage2003;
20: 870–888.
55.
SmithSMJenkinsonMWoolrichMW, et al.
Advances in functional and structural MR image analysis and implementation as FSL. NeuroImage2004;
23 Suppl 1: S208–219.
56.
ChappellMAGrovesARWhitcherB, et al.
Variational Bayesian inference for a nonlinear forward model. IEEE Trans Signal Process2009;
57: 223–236.
57.
BuxtonRBFrankLRWongEC, et al.
A general kinetic model for quantitative perfusion imaging with arterial spin labeling. Magn Reson Med1998;
40: 383–396.
DmitrienkoAD’AgostinoR.Traditional multiplicity adjustment methods in clinical trials. Stat Med2013;
32: 5172–5218.
60.
XiaMWangJHeY.BrainNet viewer: a network visualization tool for human brain connectomics. PLoS ONE2013;
8: e68910.
61.
OlsenKSVidebaekCSchmidtJF, et al.
The effect of ketanserin on cerebral blood flow and cerebrovascular CO2 reactivity in healthy volunteers. Acta Neurochir (Wien)1992;
119: 7–11.
62.
Andrews-HannaJRSmallwoodJSprengRN.The default network and self-generated thought: component processes, dynamic control, and clinical relevance. Ann N Y Acad Sci2014;
1316: 29–52.
63.
NicholsDE.Psilocybin: from ancient magic to modern medicine. J Antibiot (Tokyo)2020;
73: 679–686.
64.
BeliveauVGanzMFengL, et al.
A high-resolution in vivo atlas of the human brain’s serotonin system. J Neurosci2017;
37: 120–128.
65.
DossMKMaddenMBGaddisA, et al.
Models of psychedelic drug action: modulation of cortical-subcortical circuits. Brain J Brain2022;
145: 441–456.
66.
VollenweiderFXGeyerMA.A systems model of altered consciousness: integrating natural and drug-induced psychoses. Brain Res Bull2001;
56: 495–507.
67.
GründerGYokoiFOffordSJ, et al.
Time course of 5-HT2A receptor occupancy in the human brain after a single oral dose of the putative antipsychotic drug MDL 100,907 measured by positron emission tomography. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol1997;
17: 175–185.
68.
NordstromA-LManssonMJovanovicH, et al.
PET analysis of the 5-HT2A receptor inverse agonist ACP-103 in human brain. Int J Neuropsychopharmacol2008;
11: 163–171.
69.
Gouzoulis-MayfrankESchreckenbergerMSabriO, et al.
Neurometabolic effects of psilocybin, 3,4-methylenedioxyethylamphetamine (MDE) and d-methamphetamine in healthy volunteers. A double-blind, placebo-controlled PET study with [18F]FDG. Neuropsychopharmacology1999;
20: 565–581.
70.
BuxtonRBFrankLR.A model for the coupling between cerebral blood flow and oxygen metabolism during neural stimulation. J Cereb Blood Flow Metab Off J Tab1997;
17: 64–72.
71.
AubertACostalatR.A model of the coupling between brain electrical activity, metabolism, and hemodynamics: application to the interpretation of functional neuroimaging. NeuroImage2002;
17: 1162–1181.
72.
VidyasagarRGreylingADraijerR, et al.
The effect of black tea and caffeine on regional cerebral blood flow measured with arterial spin labeling. J Cereb Blood Flow Metab Off J Tab2013;
33: 963–968.
73.
FieldASLaurientiPJYenY-F, et al.
Dietary caffeine consumption and withdrawal: confounding variables in quantitative cerebral perfusion studies?Radiology2003;
227: 129–135.
74.
LuntMJRagabSBirchAA, et al.
Comparison of caffeine-induced changes in cerebral blood flow and middle cerebral artery blood velocity shows that caffeine reduces middle cerebral artery diameter. Physiol Meas2004;
25: 467–474.
75.
CameronOGModellJGHariharanM.Caffeine and human cerebral blood flow: a positron emission tomography study. Life Sci1990;
47: 1141–1146.
76.
DagerSRLaytonMEStraussW, et al.
Human brain metabolic response to caffeine and the effects of tolerance. Am J Psychiatry1999;
156: 229–237.
77.
DagerSRFriedmanSD.Brain imaging and the effects of caffeine and nicotine. Ann Med2000;
32: 592–599.
78.
MuegglerTRazouxFRussigH, et al.
Mapping of CBV changes in 5-HT(1A) terminal fields by functional MRI in the mouse brain. Eur Neuropsychopharmacol J Eur Opsychopharmacol2011;
21: 344–353.
79.
SharpTBarnesNM.Central 5-HT receptors and their function; present and future. Neuropharmacology2020;
177: 108155.
80.
TodaNOkamuraT.Comparison of the response to 5-carboxamidotryptamine and serotonin in isolated human, monkey and dog coronary arteries. J Pharmacol Exp Ther1990;
253: 676–682.
WatanabeSMatsumotoTAndoM, et al.
Multiple activation mechanisms of serotonin-mediated contraction in the carotid arteries obtained from spontaneously hypertensive rats. Pflugers Arch2016;
468: 1271–1282.
83.
MatsumotoTWatanabeSTaguchiK, et al.
Mechanisms underlying increased serotonin-induced contraction in carotid arteries from chronic type 2 diabetic Goto-Kakizaki rats. Pharmacol Res2014;
87: 123–132.
84.
AslanSXuFWangPL, et al.
Estimation of labeling efficiency in pseudo-continuous arterial spin labeling. Magn Reson Med2010;
63: 765–771.
85.
ChenZZhangXYuanC, et al.
Measuring the labeling efficiency of pseudocontinuous arterial spin labeling. Magn Reson Med2017;
77: 1841–1852.
86.
Erkizia-SantamaríaIAlles-PascualRHorrilloI, et al.
Serotonin 5-HT2A, 5-HT2c and 5-HT1A receptor involvement in the acute effects of psilocybin in mice. In vitro pharmacological profile and modulation of thermoregulation and head-twich response. Biomed Pharmacother Biomedecine Pharmacother2022;
154: 113612.
87.
HolzeFLeyLMüllerF, et al.
Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects. Neuropsychopharmacology2022;
47: 1180–1187.
88.
MustafaSThulesiusOIsmaelHN.Hyperthermia-induced vasoconstriction of the carotid artery, a possible causative factor of heatstroke. J Appl Physiol (1985)2004;
96: 1875–1878.
89.
AlsopDCDetreJAGolayX, et al.
Recommended implementation of arterial spin-labeled perfusion MRI for clinical applications: a consensus of the ISMRM perfusion study group and the european consortium for ASL in dementia: Recommended implementation of ASL for clinical applications. Magn Reson Med2015;
73: 102–116.
90.
PiercePAPeroutkaSJ.Hallucinogenic drug interactions with neurotransmitter receptor binding sites in human cortex. Psychopharmacology (Berl)1989;
97: 118–122.
91.
VivianiRSimE-JLoH, et al.
Components of variance in brain perfusion and the design of studies of individual differences: the baseline study. NeuroImage2009;
46: 12–22.
92.
GasserPHolsteinDMichelY, et al.
Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. J Nerv Ment Dis2014;
202: 513–520.
93.
Carhart-HarrisRLMuthukumaraswamySRosemanL, et al.
Neural correlates of the LSD experience revealed by multimodal neuroimaging. Proc Natl Acad Sci U S A2016;
113: 4853–4858.
94.
LassenNA.Cerebral blood flow and oxygen consumption in man. Physiol Rev1959;
39: 183–238.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
